Provera and the Progestin Withdrawal Bleed: What Bleeding, or Not Bleeding, Actually Tells You

A short course of a progestin to bring on a missed period is one of the most commonly prescribed things in gynaecology, and almost nobody explains the part that matters. The bleed is not the treatment. The bleed is a test result. Whether it arrives, and whether it arrives at all, tells a clinician something specific about why the periods stopped. This guide covers the label doses, how long it takes, what a negative result means, and where the withdrawal bleed is the wrong tool entirely.

What a withdrawal bleed actually is

The lining of the uterus is built by estrogen. Through the first half of a normal cycle, estrogen from developing follicles drives the endometrium to proliferate and thicken. After ovulation, progesterone from the corpus luteum stops that growth and converts the tissue to a secretory state, stabilising it. When the corpus luteum dies and progesterone falls away, the stabilised lining sheds in an organised fashion. That shed is a period.

A progestin course reproduces the second half of that sequence artificially. You take a progestin for five to ten days, which converts whatever lining is present into a secretory state. Then you stop, progestin levels fall, and the lining sheds. The bleeding that follows is a withdrawal bleed, and it is chemically the same event as the end of a natural cycle, minus the ovulation that should have preceded it.

That distinction is the reason the bleed is diagnostic. It only works if there is a lining to shed. And there is only a lining to shed if estrogen has been building one.

The progesterone challenge and what a bleed rules in

Used deliberately, the progestin course is called a progesterone challenge test, and it splits the possible causes of absent periods into two groups in about a week.

If bleeding follows, three things have been demonstrated at once. The ovaries are producing enough estrogen to build an endometrium. The endometrium is responsive. And the outflow tract, meaning cervix and vagina, is open. That narrows the cause considerably. What is missing in that case is usually ovulation itself, which points towards conditions like polycystic ovary syndrome, hypothalamic dysfunction with preserved estrogen, or raised prolactin, rather than towards ovarian failure or a structural problem.

If no bleeding follows, at least one of those three conditions is not met. Estrogen may be too low to have built a lining, which happens in premature ovarian insufficiency, in functional hypothalamic amenorrhea from low body weight or heavy training, and after certain treatments. The endometrium may be damaged or scarred, as in Asherman syndrome. Or the outflow tract may be obstructed. Those are different investigations with different implications, and the failed challenge is what sends a clinician down that path rather than continuing to prescribe progestins that will not work.

A negative result is not a failure of treatment. It is information, and it is the reason the test is worth doing rather than simply waiting.

Medroxyprogesterone dosing from the label

Medroxyprogesterone acetate tablets are approved for secondary amenorrhea and for abnormal uterine bleeding from hormonal imbalance, in the absence of structural pathology such as fibroids or uterine cancer.

The label dose for secondary amenorrhea is 5 or 10 mg daily for 5 to 10 days. Therapy can be started at any time, since there is no cycle to align with. Where the goal is optimum secretory change in an endometrium already primed by the body's own estrogen or by prescribed estrogen, the label specifies 10 mg daily for 10 days.

For cycling a woman who has a history of irregular bleeding, the label describes starting on the calculated 16th or 21st day of the cycle and giving 5 or 10 mg daily for 5 to 10 days, with the 10 mg for 10 days from day 16 regimen suggested for full secretory transformation.

Withdrawal bleeding usually begins within three to seven days of the last tablet. That is the figure to hold: not three to seven days from the first tablet, from the last one.

Micronized progesterone as the alternative, with numbers

Oral micronized progesterone is the other approved option for secondary amenorrhea, and the label gives something medroxyprogesterone labelling does not: actual response rates.

The approved dose is 400 mg as a single bedtime dose for 10 days. In a placebo controlled trial in estrogen primed postmenopausal women, 300 mg daily produced withdrawal bleeding within seven days of the last dose in 80 percent of women, against 10 percent on placebo.

A post-marketing open label study in premenopausal women with secondary amenorrhea of at least 90 days gave two 28 day cycles of a 10 day course. At 300 mg daily, 73.8 percent of 107 women bled. At 400 mg daily, 76.8 percent of 99 women bled. The extra 100 mg bought three percentage points.

A separate endpoint from the same labelling is worth knowing because it corrects a common assumption. In estrogen primed postmenopausal women, 400 mg daily for 10 days produced complete secretory change in the endometrium in 45 percent of the 22 women biopsied. Bleeding and full secretory transformation are not the same outcome, and a bleed does not prove the lining was completely converted.

Agent	Label dose for secondary amenorrhea	Time to bleeding	Notable
Medroxyprogesterone acetate	5 or 10 mg daily for 5 to 10 days	3 to 7 days after last dose	Response rate not quantified on label
Micronized progesterone	400 mg at bedtime for 10 days	Within 7 days of last dose	73.8 to 80 percent bled across studies; causes drowsiness, hence bedtime dosing; some formulations contain peanut oil
Dydrogesterone	Commonly 10 mg twice daily for 5 to 10 days	Within days of stopping	Not approved in the United States; no sedating metabolites

Pregnancy has to be excluded first, and this is not negotiable

A missed period has one common cause that no hormone course treats, and progestins are contraindicated in pregnancy. Medroxyprogesterone labelling lists undiagnosed abnormal genital bleeding among its contraindications and directs that pregnancy be considered before use.

Two points that get confused constantly. A progestin course is not an abortifacient and will not end a pregnancy; taking one while pregnant is an exposure to avoid, not a termination. And a withdrawal bleed is not a pregnancy test. If a test is positive, the progestin course is the wrong action entirely, and a bleed that follows one anyway needs urgent assessment rather than reassurance.

Take a pregnancy test before the first tablet. Every time, including when you are sure.

What the course does not do

A progestin course does not restore ovulation. It sheds a lining and then the underlying problem resumes, which is why women with PCOS often need a repeat course every one to three months until the cause is addressed. The point of repeating it is not to feel normal; it is to stop the endometrium sitting under unopposed estrogen indefinitely, which raises the risk of hyperplasia and ultimately endometrial cancer.

It is also not contraception. A short progestin course does not suppress ovulation reliably and provides no protection at all. Women who bleed after a challenge test have demonstrated a functioning estrogen supply, and some of them ovulate in the cycle that follows. If you do not want to conceive, use contraception during and after the course.

And it will not induce a period in someone whose estrogen is too low to have built a lining. Repeating the course at a higher dose does not fix that; it means the answer to the test was no, and the next step is measuring FSH, estradiol, prolactin and thyroid function rather than writing another prescription.

Side effects and who should not take it

Common effects of a short progestin course are breast tenderness, bloating, mood change, headache, nausea and irregular spotting before the main bleed. Micronized progesterone adds drowsiness and dizziness, which is why the label instructs bedtime dosing, and occasionally blurred vision, difficulty speaking or unsteady walking.

The contraindications on the medroxyprogesterone label are undiagnosed abnormal genital bleeding, known or suspected breast cancer or a history of it, known or suspected estrogen or progesterone dependent tumours, and active arterial thromboembolic disease such as stroke or myocardial infarction, or a history of either.

One item from the label that gets missed: some women on medroxyprogesterone show reduced glucose tolerance, so anyone with diabetes should be monitored during treatment. Any unexpected vaginal bleeding during therapy should be investigated rather than attributed to the drug.

If you have a uterus and the bleeding pattern is persistent or recurrent and undiagnosed, adequate assessment including endometrial sampling where indicated should come before repeat hormone courses, not after several of them.

Depot medroxyprogesterone is a different drug entirely

The confusion here is caused by shared branding rather than pharmacology. Depot medroxyprogesterone acetate, the 150 mg per mL injection given every three months, is a contraceptive. It suppresses ovulation, thins the endometrium and commonly stops periods altogether rather than inducing them.

Taking the two as interchangeable because the name is similar produces exactly the wrong outcome. Tablets induce a bleed. The depot injection removes them. If your prescription says one and your pharmacy offers the other, that is worth a phone call.

Progestin products stocked at SafeRxPills

Product	Molecule	Strength	Price
Meprate 10	Medroxyprogesterone acetate	10 mg tablet	$23.00
Deviry SR 30mg	Medroxyprogesterone acetate	30 mg sustained release	$40.00
Depo-Provera	Medroxyprogesterone acetate, contraceptive depot	150 mg per mL	$35.00
Duphaston 10mg	Dydrogesterone	10 mg	$65.00
Susten 200mg Softgel	Micronized progesterone	200 mg	$45.00
Susten 400 Softgel	Micronized progesterone	400 mg	$82.50
Gestoford 200mg	Micronized progesterone	200 mg	$80.00
Progynova 2mg	Estradiol valerate	2 mg	$37.50

The estradiol entry is there for a reason. Where a challenge test produces no bleeding because estrogen is low, the follow up test is an estrogen and progestin course together, which builds a lining first and then sheds it. Bleeding on that combined course points to an estrogen supply problem; still no bleeding points to the endometrium or the outflow tract.

What to hold onto

Take the pregnancy test first. Expect bleeding three to seven days after the last tablet rather than during the course. If nothing comes, that is a result worth acting on, not a dose to double, and the next conversation is about FSH, estradiol, prolactin and thyroid function. And if you are using a progestin course repeatedly to manage cycles that are not happening on their own, the course is buying endometrial safety while the underlying cause goes unaddressed, which is a reasonable holding position and a poor destination.

For the conditions that most often sit behind absent ovulation, see our guides to metformin in polycystic ovary syndrome, cabergoline for raised prolactin, and clomiphene for ovulation induction. If the goal after restoring a cycle is conception, progesterone for luteal phase support covers the other half of the picture, and the female infertility overview ties them together.

This article is for information only and is not a substitute for advice from a qualified prescriber. Progestins are prescription medicines. Pregnancy must be excluded before starting a course, and persistent or recurrent absent periods need a diagnosis rather than repeated hormone courses.

References

• DailyMed and FDA label, medroxyprogesterone acetate tablets: indications for secondary amenorrhea and abnormal uterine bleeding, dosage of 5 or 10 mg for 5 to 10 days, timing of withdrawal bleeding, contraindications, glucose tolerance precaution and endometrial sampling guidance
• DailyMed and FDA label, micronized progesterone capsules: 400 mg at bedtime for 10 days in secondary amenorrhea, placebo controlled withdrawal bleeding rates at 300 mg, post-marketing open label rates at 300 mg and 400 mg in premenopausal women, secretory transformation rate on biopsy, central nervous system effects and peanut oil excipient
• Pfizer prescribing information for medroxyprogesterone acetate tablets, dosage and administration and warnings sections
• US FDA Drugs at FDA label archive for medroxyprogesterone acetate, including Women's Health Initiative findings referenced in the warnings for combined estrogen and progestin therapy